Inj., tildrakizumab, 1 mg
Products billed under this code include Ilumya.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ilumya.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ilumya | Sun Pharmaceutical Global FZE. | 47335-0177-95 | 100 | $12,096.50 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $120.965 | −$3.308 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $124.273 | +$6.074 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $118.199 | −$5.586 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $123.785 | −$3.668 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $127.453 | +$1.215 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $126.238 | −$5.224 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $131.462 | −$1.716 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $133.178 | −$2.745 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $135.923 | +$2.372 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $133.551 | +$1.459 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $132.092 | −$0.483 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $132.575 | −$3.081 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $135.656 | −$7.609 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $143.265 | +$5.438 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $137.827 | +$0.395 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $137.432 | −$1.848 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $139.28 | +$0.645 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $138.635 | +$1.362 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $137.273 | +$3.679 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $133.594 | −$0.481 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $134.075 | −$1.295 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $135.37 | −$0.388 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $135.758 | +$3.05 | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $132.708 | – | 1 MG | Inj., tildrakizumab, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.